Literature DB >> 14638923

Beta1-adrenergic blockade augments pulsatile PTH secretion in humans.

Claus P Schmitt1, Jennifer Obry, Reinhard Feneberg, Johannes D Veldhuis, Otto Mehls, Eberhard Ritz, Franz Schaefer.   

Abstract

Pulsatile peptide hormone secretion provides efficient control of specific end organ functions. To test the hypothesis that sympathetic neuronal activity drives synchronous pulsatile PTH release from the parathyroid glands, we investigated the acute effects of beta1-adrenergic receptor blockade on PTH secretion patterns in a single-blinded study in nine healthy adults. Plasma PTH levels were determined at 1-min intervals. After a 75-min baseline period, seven subjects received a continuous intravenous infusion of the short-acting beta1-adrenergic receptor blocker esmolol for 105 min. After a 30-min washout period, esmolol was infused for another 30 min. Two additional subjects were randomized to receive solvent infusions. PTH secretion characteristics were analyzed by multiparameter deconvolution analysis, and the orderliness of plasma PTH fluctuations by Approximate Entropy statistics. BP slightly decreased during esmolol infusion, whereas heart rate, ionized calcium, phosphate, magnesium, and plasma and urine catecholamines remained unchanged. Esmolol increased mean plasma PTH by 33 +/- 8% (P < 0.01), due to a preferential increase in the pulsatile PTH secretion component (+129 +/- 44%, P < 0.02). The increased pulsatile PTH secretion was mediated by an augmented PTH burst mass (+117 +/- 42%, P < 0.01), whereas burst frequency remained unchanged. The regularity of PTH fluctuations was not affected by the beta-adrenergic blockade. The effects were reproducible during the second esmolol infusion. The authors conclude that the sympathetic nervous system has a modulating effect on pulsatile PTH secretion. Selective beta-1 adrenergic blockade acutely increases plasma PTH by augmenting the mass of hormone secreted per burst, but it does not alter the rhythmicity of pulsatile PTH release.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638923     DOI: 10.1097/01.asn.0000101240.47747.7f

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  10 in total

Review 1.  The role of vitamin D in pathophysiology and treatment of fibromyalgia.

Authors:  Carlos A S Jesus; David Feder; Mario F P Peres
Journal:  Curr Pain Headache Rep       Date:  2013-08

2.  A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover.

Authors:  Mara J Horwitz; Mary Beth Tedesco; Susan M Sereika; Linda Prebehala; Caren M Gundberg; Bruce W Hollis; Alessandro Bisello; Adolfo Garcia-Ocaña; Raquel M Carneiro; Andrew F Stewart
Journal:  J Bone Miner Res       Date:  2011-09       Impact factor: 6.741

3.  β-Adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects.

Authors:  K A Toulis; K Hemming; S Stergianos; K Nirantharakumar; J P Bilezikian
Journal:  Osteoporos Int       Date:  2013-10-10       Impact factor: 4.507

Review 4.  Cardiovascular Autonomic Dysfunction: Link Between Multiple Sclerosis Osteoporosis and Neurodegeneration.

Authors:  Zohara Sternberg
Journal:  Neuromolecular Med       Date:  2018-02-10       Impact factor: 3.843

5.  Efficacy and safety of weekly vitamin D3 in patients with fibromyalgia: 12-week, double-blind, randomized, controlled placebo trial.

Authors:  Luis Iván Lozano-Plata; David Vega-Morales; Jorge Antonio Esquivel-Valerio; Mario Alberto Garza-Elizondo; Dionicio A Galarza-Delgado; Karina Silva-Luna; Griselda Serna-Peña; Janeth Sifuentes-Ramírez; Alfredo de Jesús Garza-Guerra; Raúl Díaz-Niño de Rivera
Journal:  Clin Rheumatol       Date:  2021-02-10       Impact factor: 2.980

Review 6.  Vitamin D in chronic kidney disease.

Authors:  Yahn-Yir Chau; Juhi Kumar
Journal:  Indian J Pediatr       Date:  2012-04-29       Impact factor: 1.967

Review 7.  Structural organization and biological relevance of oscillatory parathyroid hormone secretion.

Authors:  C P Schmitt; M Hömme; F Schaefer
Journal:  Pediatr Nephrol       Date:  2005-02-08       Impact factor: 3.714

Review 8.  Antihypertensive Drugs and Risk of Bone Fractures.

Authors:  Maria Velliou; Elias Sanidas; Aliki Zografou; Dimitrios Papadopoulos; Nikolaos Dalianis; John Barbetseas
Journal:  Drugs Aging       Date:  2022-06-27       Impact factor: 4.271

9.  Negative association between serum parathyroid hormone levels and urinary perchlorate, nitrate, and thiocyanate concentrations in U.S. adults: the National Health and Nutrition Examination Survey 2005-2006.

Authors:  Wen-Ching Ko; Chien-Liang Liu; Jie-Jen Lee; Tsang-Pai Liu; Po-Sheng Yang; Yi-Chiung Hsu; Shih-Ping Cheng
Journal:  PLoS One       Date:  2014-12-16       Impact factor: 3.240

10.  Association of parathyroid hormone and vitamin D with untreated hypertension: Is it different in white-coat or sustained hypertension?

Authors:  Ferit Akgül; Alper Serçelik; Hakan Çetin; Turgay Erten
Journal:  PLoS One       Date:  2017-11-27       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.